LV11543B - Sin-1a cyclodextrin inclusion complexes - Google Patents

Sin-1a cyclodextrin inclusion complexes Download PDF

Info

Publication number
LV11543B
LV11543B LVP-95-383A LV950383A LV11543B LV 11543 B LV11543 B LV 11543B LV 950383 A LV950383 A LV 950383A LV 11543 B LV11543 B LV 11543B
Authority
LV
Latvia
Prior art keywords
sin
cyclodextrin
complexes
optionally
ions
Prior art date
Application number
LVP-95-383A
Other languages
English (en)
Latvian (lv)
Other versions
LV11543A (lv
Inventor
G Czy Joseph
Vikmon Andrasnu
Jozsef Szejtli
Szente Lajos
Szeman Julianna
Original Assignee
Therabel Research Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Research Sa filed Critical Therabel Research Sa
Publication of LV11543A publication Critical patent/LV11543A/xx
Publication of LV11543B publication Critical patent/LV11543B/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
LVP-95-383A 1994-04-26 1995-12-22 Sin-1a cyclodextrin inclusion complexes LV11543B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9401183A HU218280B (en) 1994-04-26 1994-04-26 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
PCT/HU1995/000011 WO1995029172A1 (en) 1994-04-26 1995-04-25 N-morpholino-n-nitrosaminoacetonitril cyclodextrin inclusion complexes

Publications (2)

Publication Number Publication Date
LV11543A LV11543A (lv) 1996-10-20
LV11543B true LV11543B (en) 1996-12-20

Family

ID=10985114

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-383A LV11543B (en) 1994-04-26 1995-12-22 Sin-1a cyclodextrin inclusion complexes

Country Status (32)

Country Link
US (1) US5698535A (bg)
EP (1) EP0705255B1 (bg)
JP (1) JP3434828B2 (bg)
KR (1) KR960703404A (bg)
CN (1) CN1060164C (bg)
AT (1) ATE197708T1 (bg)
AU (1) AU694219B2 (bg)
BG (1) BG61974B1 (bg)
BR (1) BR9506155A (bg)
CA (1) CA2163539C (bg)
CZ (1) CZ316395A3 (bg)
DE (1) DE69519463T2 (bg)
DK (1) DK0705255T3 (bg)
ES (1) ES2153897T3 (bg)
FI (1) FI956156A (bg)
GR (1) GR3035356T3 (bg)
HR (1) HRP950249A2 (bg)
HU (1) HU218280B (bg)
IL (1) IL113491A (bg)
LT (1) LT4167B (bg)
LV (1) LV11543B (bg)
MD (1) MD1419G2 (bg)
NO (1) NO311030B1 (bg)
NZ (1) NZ285149A (bg)
PL (1) PL312183A1 (bg)
PT (1) PT705255E (bg)
RO (1) RO114449B1 (bg)
RU (1) RU2136698C1 (bg)
SI (1) SI0705255T1 (bg)
SK (1) SK155195A3 (bg)
WO (1) WO1995029172A1 (bg)
YU (1) YU25995A (bg)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO2001036490A2 (en) * 1999-11-12 2001-05-25 Pitha & Pitha Llc Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
AU2003295344B2 (en) * 2002-10-09 2008-01-31 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス, インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
AU2010321533A1 (en) * 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2019074886A1 (en) 2017-10-09 2019-04-18 Terumo Bct Biotechnologies, Llc LYOPHILIZATION CONTAINER AND METHOD OF USE
EP3937878A2 (en) 2019-03-14 2022-01-19 Terumo BCT Biotechnologies, LLC Lyophilization loading tray assembly and system
CN116249522A (zh) * 2020-07-20 2023-06-09 深圳迈瑞生物医疗电子股份有限公司 一种组合物的血小板解聚用途、解聚试剂及解聚方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208233A (en) * 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
HU212730B (en) * 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
ES2112332T3 (es) * 1991-09-24 1998-04-01 Us Health Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
US5389675A (en) * 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents

Also Published As

Publication number Publication date
WO1995029172A1 (en) 1995-11-02
NZ285149A (en) 1998-06-26
DE69519463T2 (de) 2001-06-28
PT705255E (pt) 2001-05-31
LV11543A (lv) 1996-10-20
CA2163539A1 (en) 1995-11-02
MD950440A (en) 1997-10-31
IL113491A (en) 2002-03-10
CN1060164C (zh) 2001-01-03
HU218280B (en) 2000-07-28
AU2415995A (en) 1995-11-16
FI956156A0 (fi) 1995-12-20
RU2136698C1 (ru) 1999-09-10
BG100313A (bg) 1996-07-31
NO955283D0 (no) 1995-12-22
LT95133A (en) 1996-10-25
EP0705255A1 (en) 1996-04-10
AU694219B2 (en) 1998-07-16
CN1128028A (zh) 1996-07-31
FI956156A (fi) 1995-12-20
LT4167B (en) 1997-06-25
SK155195A3 (en) 1997-05-07
US5698535A (en) 1997-12-16
YU25995A (sh) 1998-08-14
DE69519463D1 (de) 2000-12-28
DK0705255T3 (da) 2000-12-11
RO114449B1 (ro) 1999-04-30
HUT70750A (en) 1995-10-30
NO955283L (no) 1995-12-22
ES2153897T3 (es) 2001-03-16
KR960703404A (ko) 1996-08-17
JPH09503546A (ja) 1997-04-08
CZ316395A3 (en) 1996-05-15
BG61974B1 (bg) 1998-11-30
NO311030B1 (no) 2001-10-01
SI0705255T1 (en) 2001-04-30
HU9401183D0 (en) 1994-07-28
CA2163539C (en) 2003-04-01
ATE197708T1 (de) 2000-12-15
HRP950249A2 (en) 1997-10-31
GR3035356T3 (en) 2001-05-31
MD1419G2 (ro) 2000-11-30
BR9506155A (pt) 1996-04-16
MD1419F2 (en) 2000-02-29
EP0705255B1 (en) 2000-11-22
PL312183A1 (en) 1996-04-01
JP3434828B2 (ja) 2003-08-11
IL113491A0 (en) 1995-07-31

Similar Documents

Publication Publication Date Title
US5698535A (en) SIN-1A cyclodextrin inclusion complexes
JP5021318B2 (ja) β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤
JPH08506119A (ja) 認識活性化剤CI−979HC▲l▼の中性安定化複合体
EP0477315B1 (en) Inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine or salts formed with cyclodextrin derivatives, preparation thereof and pharmaceutical compositions containing the same
EP0478732B1 (en) Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
Singh et al. Physicochemical and Biological Studies of Inclusion Complex of Methotrexate with β‐Cyclodextrin
MXPA06008032A (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
SK278809B6 (sk) Inklúzny komplex 3-morfolinosydnonimínu alebo jeho